Skip to main content

ExonHit to Buy RedPath Integrated Pathology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics said today that it has agreed to buy personalized diagnostics company RedPath Integrated Pathology in a deal that could be worth a total of $32 million.

Paris-based ExonHit plans to buy RedPath, a developer of DNA-based cancer tests, for $12.5 million upfront, another $10 million in stock, and for sales milestone payments that could total another $9.5 million.

RedPath, which is headquartered in Pittsburgh, Penn., has launched the PathFinderTG molecular diagnostic assay for pancreatic cancer, and it is developing another test to differentiate primary from metastasis tumors. RedPath also has two testing service programs in late-stage development and several earlier-stage development programs also focused on oncology testing, ExonHit said.

"The acquisition of RedPath is a significant milestone in ExonHit’s strategy to become an internationally recognized player in molecular diagnostics," Loic Maurel, president of ExonHit's management board, said in a statement.

Maurel said that the deal will strengthen ExonHit’s US presence, which he said represents around 55 percent of the molecular diagnostics market. He also said that the acquisition “will give ExonHit a new dimension, with an innovative offering in oncology, the fastest-growing segment in molecular diagnostics.”

Integrating RedPath’s DNA technology with ExonHit’s RNA-based platform business “will allow for the possibility of more accurate diagnostic tests” and will give the firm a stronger IP position, ExonHit said.

The deal, which is subject to approval by ExonHit’s shareholders at an upcoming meeting, is expected to close before mid-July.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.